| Name | Title | Contact Details |
|---|
HotSpot Therapeutics is discovering new allosteric therapies with the ability to treat disease in new ways.
At Strive Compounding Pharmacy, were pioneering a movement in personalized medicine. Ditching the one-size-fits-all approach, we specialize in customizing medications to fit the unique health conditions and wellness goals of each individual. Our commitment to whole-person health is evident in our comprehensive services ranging from hormone replacement and weight management to dermatology and veterinary care. As a rapidly growing company, we pride ourselves on our robust company culture, strong partnerships with healthcare providers, and the effectiveness, safety, and benefits of our compounded drugs. Our pursuit of uncompromised excellence in compounding, coupled with a proactive approach to healthcare, sets us apart in creating healthier and happier lives, while also educating the world on the crucial role that compound pharmacies play within a healthy society.
XOMA is a late-stage biotechnology company with a diverse portfolio of innovative therapeutic antibodies. The Company has built an expertise in allosteric modulation and has applied that expertise to expand the therapeutic potential of monoclonal antibodies. The first compound from XOMA’s allosteric modulating antibody program is gevokizumab, an IL-1 beta modulating antibody. XOMA has partnered with SERVIER, a global pharmaceutical company based in France, to develop and commercialize gevokizumab for the global market, and the companies are conducting a global Phase 3 program in people with Behçet’s disease uveitis and non-infectious uveitis. Each company also has a proof-of-concept (POC) clinical program in place to identify other IL-1 mediated diseases that could be treated with gevokizumab. One of these POC studies led XOMA to select its next Phase 3 indication, pyoderma gangrenosum, a rare ulcerative skin disease. XOMA`s scientific research also produced the XMet program, which consists of three classes of preclinical allosteric modulating antibodies, including Selective Insulin Receptor Modulators (SIRMs) that could have a major impact on the treatment of diabetes. XOMA will retain the compound that has potential to treat several rare insulin dysfunction-related diseases and to out-license the compounds that could address the diabetes markets.
BionorImmuno is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Verseon is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.